This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to tirzepatide through licensed providers and compounding pharmacy partners. Always consult a qualified healthcare provider before starting any prescription medication.
Most weight management medications work on a single lever. They suppress appetite, slow digestion, or nudge insulin secretion — one mechanism, one target. For decades, that was the ceiling. Then researchers asked a different question: what happens when you activate two complementary hormonal pathways at the same time?
Tirzepatide is the compound that answered it. Here is how the dual agonist mechanism works, what the SURMOUNT and SURPASS trial programs demonstrated, and how to evaluate whether it is clinically relevant for you.
Key Takeaways
- Regulatory Status: FDA-approved for type 2 diabetes as Mounjaro in 2022, for chronic weight management as Zepbound in November 2023, and for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024. Compounded tirzepatide has been available through 503A pharmacies during shortage periods; FDA shortage status should be confirmed with your provider.
- Research Stage: Approved and extensively studied across the SURPASS (T2D) and SURMOUNT (obesity) trial programs
- Availability: Prescription only through Superpower's licensed provider network and compounding pharmacy partners. Tirzepatide is not available in all states. It is currently not available in New York, New Jersey, California, South Carolina, Alabama, Arkansas, or Louisiana.
- Prescribing information: Mounjaro (T2D) — DailyMed · Zepbound (weight/OSA) — DailyMed
- How it works: Co-activates GIP and GLP-1 receptors to reduce appetite, slow gastric emptying, and improve insulin sensitivity.
- What the research shows: In SURMOUNT-1 (N = 2,539), participants without diabetes achieved mean weight reductions of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg versus 3.1% with placebo at 72 weeks; individual results varied by dose and baseline characteristics.
What Is Tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide that functions as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is the first approved compound in the "twincretin" class. Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide activates two separate incretin axes simultaneously, producing effects on appetite regulation, gastric emptying, insulin secretion, and fat metabolism that exceed what either pathway produces in isolation.
Tirzepatide was developed by Eli Lilly and Company. It received FDA approval in May 2022 under the brand name Mounjaro for the management of type 2 diabetes, and in November 2023 under the brand name Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. In December 2024, Zepbound received an additional FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity. Tirzepatide is administered as a once-weekly subcutaneous injection. A baseline assessment of insulin sensitivity and glycemic status is typically part of provider evaluation before initiation.
All randomized controlled trial data cited in this article were generated using FDA-approved branded formulations of tirzepatide (Mounjaro, Zepbound). Real-world observational studies cited may include patients prescribed compounded formulations. Efficacy and safety findings from branded-formulation trials may not be directly transferable to compounded formulations.
What Tirzepatide May Support
1. Glycemic Control in Type 2 Diabetes
The SURPASS trial program evaluated tirzepatide across six phase 3 trials in adults with type 2 diabetes. In the SURPASS-1 trial published in the Lancet in 2021 by Rosenstock and colleagues, 478 adults with T2D were randomized to tirzepatide monotherapy at 5, 10, or 15 mg or placebo over 40 weeks; mean HbA1c reductions were 1.87, 1.89, and 2.07 percentage points, respectively, compared to 0.04 points for placebo, without increased hypoglycemia risk. In the SURPASS-3 trial published in the Lancet in 2021 by Ludvik and colleagues, 1,437 adults with T2D on metformin with or without an SGLT2 inhibitor were followed over 52 weeks; HbA1c reductions were 1.93% (5 mg), 2.20% (10 mg), and 2.37% (15 mg) versus 1.34% with titrated insulin degludec, and tirzepatide produced weight loss of 7.5 kg (5 mg) to 12.9 kg (15 mg) versus a 2.3 kg weight gain with insulin degludec. A 2024 network meta-analysis in Diabetologia by Karagiannis and colleagues, pooling 28 randomized controlled trials with 23,622 participants, found that tirzepatide 15 mg reduced HbA1c by 1.96 percentage points versus placebo compared to 1.59 points for semaglutide 2.0 mg, and reduced bodyweight by 9.57 kg versus 4.97 kg for semaglutide 2.0 mg; all tirzepatide doses were comparable to or superior to semaglutide 2.0 mg for HbA1c control and consistently produced greater weight loss across dose comparisons. Reference ranges vary by lab and individual; providers interpret results in context.
2. Weight Reduction in Adults With Obesity
The SURMOUNT-1 trial published in the New England Journal of Medicine in 2022 by Jastreboff and colleagues remains the landmark weight trial for tirzepatide. The trial enrolled 2,539 participants with obesity or overweight with at least one comorbidity but without type 2 diabetes and followed them over 72 weeks. At 72 weeks, mean weight reductions were 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) compared to 3.1% with placebo. Individual results varied. The SURMOUNT-4 trial published in JAMA in 2024 by Aronne and colleagues enrolled 783 participants who first received open-label tirzepatide at the maximum tolerated dose (10 or 15 mg) for 36 weeks, achieving a mean 20.9% weight loss, then randomized 670 completers to continued tirzepatide or placebo for an additional 52 weeks; continued tirzepatide produced a further 5.5% weight loss (25.3% total) while the placebo switch group regained 14.0% of bodyweight (difference of 19.4 percentage points; 95% CI 17.7–21.2; P < 0.001). These findings underscore that tirzepatide's effects on metabolic health and weight are dependent on continued use.
3. Weight Reduction in Adults With Type 2 Diabetes
The SURMOUNT-2 trial published in the Lancet in 2023 by Garvey and colleagues enrolled 938 adults with both obesity and T2D over 72 weeks, testing only the 10 mg and 15 mg doses (the 5 mg dose was not evaluated in this trial). Mean weight reductions were 12.8% (10 mg) and 14.7% (15 mg) compared to 3.2% for placebo, with treatment differences of 9.6 percentage points (95% CI 8.1–11.1) and 11.6 percentage points (95% CI 10.1–13.0), respectively (both P < 0.0001). Baseline mean HbA1c was 8.02%, and 79–83% of tirzepatide participants achieved at least 5% weight reduction versus 32% with placebo. This trial established that tirzepatide's weight-reducing effects persist in individuals with T2D, though the magnitude was somewhat lower than in SURMOUNT-1, consistent with the known attenuating effect of diabetes on weight loss outcomes. These results support the use of tirzepatide in individuals managing both conditions concurrently.
4. Obstructive Sleep Apnea
The SURMOUNT-OSA trial published in the New England Journal of Medicine in 2024 by Malhotra and colleagues enrolled 469 participants over 52 weeks and evaluated tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity. At the maximum tolerated dose of 10 or 15 mg, tirzepatide reduced the apnea-hypopnea index (AHI) by 25.3 events per hour (95% CI 21.2–29.3) in participants not using positive airway pressure therapy — a treatment difference of 20.0 events per hour versus placebo (95% CI 14.2–25.8; P < 0.001) — and by 29.3 events per hour (95% CI 25.4–33.2) in PAP users, a treatment difference of 23.8 events per hour versus placebo (95% CI 17.9–29.6; P < 0.001). Secondary outcomes included improvements in oxygen saturation, sleep quality scores, and waist circumference. This trial supported the 2024 FDA approval of Zepbound for OSA. The mechanism is primarily mediated through weight reduction and improvements in upper airway anatomy. Sleep quality biomarkers are among the relevant downstream measures for this indication.
5. Cardiovascular Outcomes
Tirzepatide's cardiovascular profile has been evaluated across multiple trials. A pre-specified meta-analysis of the SURPASS program published by Sattar and colleagues in Nature Medicine in 2022, pooling 7,215 participants (4,887 tirzepatide and 2,328 controls) across seven trials spanning 26 to 108 weeks, reported a hazard ratio for MACE-4 (composite of cardiovascular death, non-fatal MI, non-fatal stroke, and hospitalization for unstable angina) of 0.80 (95% CI 0.57–1.11) versus comparators including insulin glargine, insulin degludec, and placebo in adults with T2D. A separate phase 3 trial published by Packer and colleagues in the New England Journal of Medicine in 2024, the SUMMIT trial enrolling 731 patients (364 tirzepatide, 367 placebo) with a median follow-up of 104 weeks, reported a hazard ratio of 0.62 (95% CI 0.41–0.95; P = 0.026) for the composite of cardiovascular death or worsening heart failure — a 38% relative risk reduction — in patients with HFpEF and BMI of 30 or greater versus placebo. A 2025 Nature Medicine editorial — a commentary, not original research — discussed emerging real-world evidence suggesting comparable cardiovascular benefits for tirzepatide and semaglutide in T2D patients, though dedicated randomized cardiovascular outcome trial data for tirzepatide are still pending. Dedicated cardiovascular outcome trial data are anticipated from the ongoing SURMOUNT-MMO study. Cardiovascular health biomarkers including lipid panels and blood pressure are relevant monitoring markers.
6. Lipid and Cardiometabolic Markers
Beyond glycemic effects, tirzepatide produces meaningful changes in lipid parameters. A 2022 systematic review in the International Journal of Molecular Sciences by Forzano and colleagues, reviewing data from the SURPASS 1–5 phase 3 trials and SURMOUNT-1 enrolling more than 7,000 participants with T2D, documented dose-dependent reductions in LDL cholesterol and triglycerides across all tirzepatide arms compared to placebo and active comparators including insulin glargine and semaglutide 1.0 mg, alongside improvements in systolic blood pressure and markers of systemic inflammation. These effects appear to be partially independent of weight loss, reflecting tirzepatide's direct activity on GIP receptors in adipose tissue and hepatic lipid metabolism. Monitoring triglycerides and LDL at baseline and during therapy provides objective evidence of these secondary cardiometabolic effects.
7. Prediabetes and T2D Prevention
A 176-week extension of SURMOUNT-1 (NCT04184622) published by Jastreboff and colleagues in the New England Journal of Medicine in 2025 evaluated 1,032 participants with obesity and prediabetes randomized to tirzepatide 5 mg, 10 mg, or 15 mg or placebo. At 176 weeks, mean weight reductions were 12.3% (5 mg), 18.7% (10 mg), and 19.7% (15 mg) versus 1.3% with placebo. Type 2 diabetes developed in only 1.3% of tirzepatide-treated participants compared to 13.3% receiving placebo, a hazard ratio of 0.07 (95% CI 0.0–0.1; P < 0.001). This finding extends tirzepatide's clinical relevance beyond those with established T2D to individuals with elevated metabolic risk who have not yet crossed the diagnostic threshold. Baseline fasting insulin and HbA1c assessments are central to evaluating this risk profile.
Tirzepatide vs. Semaglutide: Key Differences
Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates GLP-1 receptors only. In head-to-head and comparative evidence, tirzepatide consistently produces greater weight reduction and HbA1c lowering than semaglutide, though both compounds carry similar gastrointestinal adverse event profiles.
The most rigorous comparative evidence comes from network meta-analyses and real-world studies rather than a single randomized controlled trial. A 2025 meta-analysis in Cureus by Munawar and colleagues, pooling seven direct comparative studies with 28,980 participants, found tirzepatide associated with significantly higher odds of achieving 10% or greater weight loss compared to semaglutide (OR 0.21; 95% CI 0.06–0.78 favoring tirzepatide) and a standardized mean difference in weight loss of 0.75 (95% CI 0.52–0.92). The Karagiannis 2024 Diabetologia meta-analysis confirmed more pronounced HbA1c and weight reduction for tirzepatide versus semaglutide in T2D across network meta-analysis. A real-world cohort study published by Rodriguez and colleagues in JAMA Internal Medicine in 2024, using propensity-score matching across 18,386 adults with overweight or obesity observed from May 2022 through November 2023, found tirzepatide associated with 2.4 percentage points greater weight loss than semaglutide at 3 months, 4.3 points at 6 months, and 6.9 points at 12 months, with a hazard ratio for achieving at least 10% weight loss of 2.54 (95% CI 2.37–2.73) favoring tirzepatide, and similar GI adverse event rates.
These comparisons involve specific doses (semaglutide 1.0 mg or 2.4 mg vs. tirzepatide 5-15 mg), specific populations, and specific study designs. Cross-trial comparisons should be interpreted with attention to those differences. Semaglutide has more extensive cardiovascular outcome trial data, including the SELECT trial by Lincoff and colleagues, which randomized 17,604 adults aged 45 or older with pre-existing cardiovascular disease and BMI of 27 or greater (without diabetes) to semaglutide 2.4 mg weekly or placebo over a mean 39.8 months and reported a hazard ratio for MACE of 0.80 (95% CI 0.72–0.90; P < 0.001). Tirzepatide's dedicated cardiovascular outcome trial is ongoing. Mechanism, evidence base, formulation availability, and individual clinical factors all inform the prescribing decision, which requires evaluation by a licensed provider.
Tirzepatide Formulations
Tirzepatide is available as a once-weekly subcutaneous injection. Brand-name formulations (Mounjaro for T2D, Zepbound for obesity and OSA) are manufactured by Eli Lilly and are available through specialty and retail pharmacies with a valid prescription. Compounded tirzepatide has been available from 503A compounding pharmacies during periods of FDA-declared shortage. The FDA removed tirzepatide from the shortage list in December 2024 via Declaratory Order, and enforcement discretion for 503A compounding ended in February 2025. As of April 2026, providers should confirm current compounding status and regulatory requirements. Compounded medications are prepared by a licensed compounding pharmacy and are not FDA-approved. They have not been evaluated by the FDA for safety, efficacy, or quality in the same manner as commercially manufactured branded products. Compounded tirzepatide may differ from the branded version in formulation, concentration, and inactive ingredients. The FDA has issued safety communications noting that compounded products may not meet the same quality standards as approved formulations. Dose titration protocols are provider-determined based on tolerability and clinical response.
Biomarkers to Monitor With Tirzepatide
A licensed provider will determine the appropriate monitoring schedule. The following biomarkers are clinically relevant given tirzepatide's mechanism and therapeutic effects:
- HbA1c: The primary glycemic monitoring marker for tirzepatide therapy. Measures average blood glucose over approximately 90 days. Meaningful reductions are typically observed at 12 to 24 weeks of therapy. Baseline and follow-up HbA1c values quantify glycemic response. Reference ranges vary by lab; providers interpret in context of individual clinical goals.
- Fasting glucose: Provides a shorter-horizon glycemic reference point than HbA1c. Relevant at baseline to characterize glycemic status and at follow-up to track incremental changes. Fasting glucose is particularly informative in the prediabetes range (100-125 mg/dL) where tirzepatide may delay progression.
- Fasting insulin: Tirzepatide improves insulin sensitivity through GIP and GLP-1 receptor co-activation. Baseline fasting insulin establishes whether insulin resistance is present and provides context for interpreting subsequent HbA1c changes.
- Lipid panel (LDL-C, triglycerides, HDL-C, non-HDL-C): SURPASS trial data demonstrated dose-dependent improvements in LDL cholesterol, triglycerides, and HDL cholesterol. Baseline lipid assessment and follow-up monitoring at 3 to 6 months capture these cardiometabolic effects. Triglycerides are among the most responsive markers. Reference ranges vary by lab and cardiovascular risk profile.
- Complete metabolic panel (CMP): Covers liver function (AST, ALT, alkaline phosphatase) and kidney function (creatinine, BUN, eGFR). Liver enzyme elevations have been reported with GLP-1 receptor agonists in some populations; baseline and periodic monitoring are standard clinical practice. eGFR is particularly relevant in individuals with pre-existing renal conditions, as tirzepatide can reduce renal perfusion pressure through blood pressure and weight effects.
- Complete blood count (CBC): Relevant at baseline to rule out underlying conditions that may affect tolerability, including anemia, which can confound fatigue-related side effect assessment.
- hs-CRP: A sensitive marker of systemic inflammation. The SURPASS trials reported reductions in inflammatory markers with tirzepatide. Monitoring hs-CRP alongside weight and glycemic markers provides an additional cardiometabolic reference point.
- Blood pressure: SURPASS data document consistent reductions in systolic and diastolic blood pressure with tirzepatide across all doses. Tracking blood pressure before and during therapy quantifies this effect, particularly in individuals with pre-existing hypertension.
HbA1c, fasting glucose, fasting insulin, and a lipid panel are the core markers for evaluating cardiometabolic baseline before starting tirzepatide. A complete metabolic panel confirms organ function. For individuals with existing cardiovascular risk factors, a comprehensive cardiovascular biomarker assessment provides additional clinical context that informs prescribing decisions.
What Tirzepatide Is Typically Prescribed For
Providers typically evaluate candidates for tirzepatide based on FDA-approved indications: type 2 diabetes requiring glycemic management, chronic weight management in adults with BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or cardiovascular disease), and moderate-to-severe obstructive sleep apnea with obesity. Baseline bloodwork confirming glycemic status, lipid profile, and organ function is standard practice before initiation. Tirzepatide requires a prescription from a licensed provider. Superpower Health facilitates access through its licensed provider network and compounding pharmacy partners.
Who Should Not Use Tirzepatide
A licensed provider will evaluate individual risk factors before prescribing. The following are contraindications or conditions requiring additional clinical scrutiny based on the FDA prescribing information:
- Personal or family history of medullary thyroid carcinoma (MTC), as GLP-1 receptor agonists have been associated with thyroid C-cell tumors in rodent studies; human relevance is uncertain but the prescribing information carries a boxed warning
- Multiple endocrine neoplasia syndrome type 2 (MEN 2), which includes an elevated risk of MTC
- Known hypersensitivity to tirzepatide or any component of the formulation
- Pregnancy, as GLP-1 receptor agonists may cause fetal harm; adequate contraception is recommended during use and for a period following discontinuation per provider guidance
- Severe gastrointestinal disease, including gastroparesis, as tirzepatide slows gastric emptying and may worsen these conditions
- History of pancreatitis, as GLP-1 receptor agonists have been associated with acute pancreatitis; the causal relationship remains under evaluation
- Diabetic retinopathy requiring treatment, as rapid improvements in glycemic control with intensive therapy have been associated with early worsening of retinopathy
Side Effects and Safety Considerations
The most common side effects of tirzepatide are gastrointestinal and are generally dose-dependent. They are most prominent during dose escalation and tend to diminish over time in most patients. A 2023 meta-analysis in the Journal of the Endocrine Society by Mishra and colleagues, pooling 10 clinical trials with 6,836 participants, reported dose-dependent GI adverse event rates of 39% (95% CI 35–43%) at 5 mg, 46% (95% CI 42–49%) at 10 mg, and 49% (95% CI 38–60%) at 15 mg, with drug discontinuation due to adverse events reaching 10% at the 15 mg dose; severe hypoglycemia and fatal adverse events each occurred in 1% or fewer of participants across all doses.
Common (reported in clinical studies):
- Nausea (most common, particularly during dose escalation; reported in approximately 24-33% of participants in SURMOUNT-1 depending on dose)
- Diarrhea (reported in approximately 17-21% in SURMOUNT-1)
- Vomiting (reported in approximately 8-13% in SURMOUNT-1)
- Constipation (reported in 7-11% in SURMOUNT-1)
- Injection-site reactions, including erythema, pruritus, and swelling (generally mild and transient)
- Decreased appetite (a primary mechanism of action; expected and reported across trials)
Less common but reported:
- Acute pancreatitis: discontinue and contact your provider promptly if you experience severe, persistent abdominal pain
- Hypoglycemia: primarily in individuals using concurrent insulin or sulfonylureas; risk is low with tirzepatide monotherapy
- Cholelithiasis (gallstones): observed with weight loss in general; reported in GLP-1 RA class; alert provider to right upper quadrant pain
- Tachycardia: a modest increase in resting heart rate (2-4 bpm) has been observed across GLP-1 RA class trials; clinical significance is uncertain in most patients
- Psychiatric symptoms (depression, anxiety): reported in 1.2% of pharmacovigilance reports for the GLP-1 RA class per a 2024 pharmacovigilance study in the International Journal of Clinical Pharmacy by Tobaiqy and colleagues; alert provider to changes in mood or behavior
- Hair loss (telogen effluvium): commonly observed in the context of rapid weight loss rather than as a direct drug effect; typically self-resolving
Is Tirzepatide Legal?
As of April 2026, tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) and for chronic weight management and obstructive sleep apnea in adults with obesity (Zepbound). Tirzepatide is not FDA-approved for any other indications. The safety and efficacy of tirzepatide for any use other than the approved indications have not been established through adequate and well-controlled clinical trials reviewed by the FDA.
Tirzepatide has been compounded under Section 503A during periods of FDA-declared shortage. FDA shortage status and associated compounding permissions are subject to change; as of April 2026, the FDA removed tirzepatide from the shortage list for all strengths in a December 2024 Declaratory Order, and enforcement discretion for 503A compounding ended in February 2025. Providers and patients should confirm current compounding status. Compounded tirzepatide is not equivalent to FDA-approved Mounjaro or Zepbound and has not undergone FDA review. It is not available over the counter.
Tirzepatide is not on the 2026 WADA Prohibited List for competition use, and no specific athletic ban applies. Its primary indications are metabolic and related to chronic disease management rather than athletic performance enhancement.
Understanding Your Baseline Before Starting Tirzepatide
Tirzepatide produces its most meaningful effects in individuals whose baseline metabolic profile documents the clinical need: elevated HbA1c, impaired fasting glucose, insulin resistance, dyslipidemia, or body composition markers consistent with obesity and cardiometabolic risk. Testing before initiation creates the reference point against which response at 12, 24, and 52 weeks can be measured. HbA1c and fasting glucose establish the glycemic baseline. Fasting insulin characterizes insulin resistance. A complete lipid panel captures the cardiometabolic context. A metabolic panel rules out contraindications. Without these baselines, the clinical significance of changes during therapy is difficult to evaluate objectively.
That principle — test first, then decide — is central to Superpower's approach to preventive health: the belief that every clinical decision should be grounded in what your bloodwork actually shows, not assumptions about what might be happening.
Frequently Asked Questions
What is the difference between tirzepatide and semaglutide?
Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates only GLP-1 receptors. In comparative trials and network meta-analyses, tirzepatide has produced greater mean weight reduction and HbA1c lowering than semaglutide at the doses studied. Semaglutide has more extensive dedicated cardiovascular outcome trial data, including the SELECT trial, which randomized 17,604 non-diabetic adults with pre-existing cardiovascular disease and BMI of 27 or greater to semaglutide 2.4 mg weekly or placebo over a mean 39.8 months and reported a hazard ratio of 0.80 (95% CI 0.72–0.90) for MACE. Both carry similar gastrointestinal side effect profiles. The prescribing decision requires clinical evaluation.
What happens to your body when you stop tirzepatide?
Weight regain is well-documented after discontinuation. In SURMOUNT-4, participants who switched from tirzepatide to placebo regained approximately 14% of body weight within 52 weeks, erasing much of the initial loss. Glycemic markers also trend toward pre-treatment values over time. This reflects the ongoing nature of the hormonal pathways tirzepatide supports; the effects are not permanent and are dependent on continued use. Providers typically discuss maintenance strategies before initiating therapy.
Is tirzepatide FDA-approved?
Yes. Tirzepatide is FDA-approved under the brand name Mounjaro for the management of type 2 diabetes in adults, approved in May 2022. Under the brand name Zepbound, it received FDA approval in November 2023 for chronic weight management in adults with obesity or overweight with weight-related comorbidities, and in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. No other uses have been approved by the FDA.
How much weight can you lose on tirzepatide in 3 months?
In SURMOUNT-1, participants taking tirzepatide achieved mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo at the 72-week primary endpoint. The trial included a 20-week dose-escalation period; published interim timepoint data at 12 weeks are approximate and derived from graphical figures rather than pre-specified analyses, with estimated reductions of roughly 5–7% depending on dose and individual characteristics. Results varied substantially across participants. Weight loss is most consistent in individuals who also implement dietary and lifestyle changes concurrent with medication use, as studied in the clinical trials.
Can you take tirzepatide without being diabetic?
Yes. Tirzepatide (as Zepbound) is FDA-approved for chronic weight management in adults without type 2 diabetes who have a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. The SURMOUNT-1 trial specifically enrolled participants without type 2 diabetes and documented the 20.9% mean weight reduction at the 15 mg dose at 72 weeks.
Is compounded tirzepatide the same as brand-name?
No. Compounded tirzepatide is not FDA-approved and has not been reviewed by the FDA for safety, efficacy, or manufacturing quality. It is prepared by 503A compounding pharmacies under state pharmacy board oversight. The FDA has issued safety communications noting that compounded products may differ from FDA-approved formulations in quality, potency, and sterility. Availability for compounding is also tied to FDA shortage status, which changes over time. A licensed provider can clarify current options.
Does tirzepatide cause hair loss?
Hair thinning associated with tirzepatide is typically attributed to telogen effluvium, a form of diffuse hair shedding triggered by significant physiological stress, including rapid weight loss. It is not considered a direct pharmacological effect of the drug. In clinical trials, hair loss was reported at low rates. Telogen effluvium is generally self-limiting and resolves within 3 to 6 months as the body adjusts to a new stable weight. Nutritional adequacy during weight loss, particularly protein intake, is clinically relevant to hair follicle maintenance.
IMPORTANT SAFETY INFORMATION
Tirzepatide is an FDA-approved prescription medication marketed as Mounjaro (type 2 diabetes), Zepbound (chronic weight management), and approved for moderate-to-severe obstructive sleep apnea in adults with obesity. The compounded formulation available through Superpower is NOT the FDA-approved drug product. Compounded tirzepatide has not been reviewed by the FDA for safety, efficacy, or manufacturing quality. Clinical trial results cited on this page were generated using FDA-approved branded formulations and may not apply to compounded versions. The availability of compounded tirzepatide is subject to ongoing regulatory developments regarding drug shortage status and FDA enforcement policy. Superpower is a technology platform; Superpower does not prescribe or dispense medications.
Boxed warning (from FDA-approved labeling): Tirzepatide causes thyroid C-cell tumors in rodents. It is unknown whether it causes MTC in humans. Do not use if you or any family member has had MTC or MEN 2.
Warnings: pancreatitis, gallbladder events, hypoglycemia, kidney injury, serious allergic reactions, gastroparesis, diabetic retinopathy complications.
Common side effects: nausea, diarrhea, vomiting, constipation, decreased appetite, abdominal pain, injection site reactions.
Pregnancy: not recommended. Discontinue at least 2 months before a planned pregnancy.
Not a complete list of risks. Full FDA-approved prescribing information at dailymed.nlm.nih.gov.
This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to tirzepatide through licensed providers and compounding pharmacy partners. Always consult a qualified healthcare provider before starting any prescription medication.
Most weight management medications work on a single lever. They suppress appetite, slow digestion, or nudge insulin secretion — one mechanism, one target. For decades, that was the ceiling. Then researchers asked a different question: what happens when you activate two complementary hormonal pathways at the same time?
Tirzepatide is the compound that answered it. Here is how the dual agonist mechanism works, what the SURMOUNT and SURPASS trial programs demonstrated, and how to evaluate whether it is clinically relevant for you.
Key Takeaways
- Regulatory Status: FDA-approved for type 2 diabetes as Mounjaro in 2022, for chronic weight management as Zepbound in November 2023, and for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024. Compounded tirzepatide has been available through 503A pharmacies during shortage periods; FDA shortage status should be confirmed with your provider.
- Research Stage: Approved and extensively studied across the SURPASS (T2D) and SURMOUNT (obesity) trial programs
- Availability: Prescription only through Superpower's licensed provider network and compounding pharmacy partners. Tirzepatide is not available in all states. It is currently not available in New York, New Jersey, California, South Carolina, Alabama, Arkansas, or Louisiana.
- Prescribing information: Mounjaro (T2D) — DailyMed · Zepbound (weight/OSA) — DailyMed
- How it works: Co-activates GIP and GLP-1 receptors to reduce appetite, slow gastric emptying, and improve insulin sensitivity.
- What the research shows: In SURMOUNT-1 (N = 2,539), participants without diabetes achieved mean weight reductions of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg versus 3.1% with placebo at 72 weeks; individual results varied by dose and baseline characteristics.
What Is Tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide that functions as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is the first approved compound in the "twincretin" class. Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide activates two separate incretin axes simultaneously, producing effects on appetite regulation, gastric emptying, insulin secretion, and fat metabolism that exceed what either pathway produces in isolation.
Tirzepatide was developed by Eli Lilly and Company. It received FDA approval in May 2022 under the brand name Mounjaro for the management of type 2 diabetes, and in November 2023 under the brand name Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. In December 2024, Zepbound received an additional FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity. Tirzepatide is administered as a once-weekly subcutaneous injection. A baseline assessment of insulin sensitivity and glycemic status is typically part of provider evaluation before initiation.
All randomized controlled trial data cited in this article were generated using FDA-approved branded formulations of tirzepatide (Mounjaro, Zepbound). Real-world observational studies cited may include patients prescribed compounded formulations. Efficacy and safety findings from branded-formulation trials may not be directly transferable to compounded formulations.
What Tirzepatide May Support
1. Glycemic Control in Type 2 Diabetes
The SURPASS trial program evaluated tirzepatide across six phase 3 trials in adults with type 2 diabetes. In the SURPASS-1 trial published in the Lancet in 2021 by Rosenstock and colleagues, 478 adults with T2D were randomized to tirzepatide monotherapy at 5, 10, or 15 mg or placebo over 40 weeks; mean HbA1c reductions were 1.87, 1.89, and 2.07 percentage points, respectively, compared to 0.04 points for placebo, without increased hypoglycemia risk. In the SURPASS-3 trial published in the Lancet in 2021 by Ludvik and colleagues, 1,437 adults with T2D on metformin with or without an SGLT2 inhibitor were followed over 52 weeks; HbA1c reductions were 1.93% (5 mg), 2.20% (10 mg), and 2.37% (15 mg) versus 1.34% with titrated insulin degludec, and tirzepatide produced weight loss of 7.5 kg (5 mg) to 12.9 kg (15 mg) versus a 2.3 kg weight gain with insulin degludec. A 2024 network meta-analysis in Diabetologia by Karagiannis and colleagues, pooling 28 randomized controlled trials with 23,622 participants, found that tirzepatide 15 mg reduced HbA1c by 1.96 percentage points versus placebo compared to 1.59 points for semaglutide 2.0 mg, and reduced bodyweight by 9.57 kg versus 4.97 kg for semaglutide 2.0 mg; all tirzepatide doses were comparable to or superior to semaglutide 2.0 mg for HbA1c control and consistently produced greater weight loss across dose comparisons. Reference ranges vary by lab and individual; providers interpret results in context.
2. Weight Reduction in Adults With Obesity
The SURMOUNT-1 trial published in the New England Journal of Medicine in 2022 by Jastreboff and colleagues remains the landmark weight trial for tirzepatide. The trial enrolled 2,539 participants with obesity or overweight with at least one comorbidity but without type 2 diabetes and followed them over 72 weeks. At 72 weeks, mean weight reductions were 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) compared to 3.1% with placebo. Individual results varied. The SURMOUNT-4 trial published in JAMA in 2024 by Aronne and colleagues enrolled 783 participants who first received open-label tirzepatide at the maximum tolerated dose (10 or 15 mg) for 36 weeks, achieving a mean 20.9% weight loss, then randomized 670 completers to continued tirzepatide or placebo for an additional 52 weeks; continued tirzepatide produced a further 5.5% weight loss (25.3% total) while the placebo switch group regained 14.0% of bodyweight (difference of 19.4 percentage points; 95% CI 17.7–21.2; P < 0.001). These findings underscore that tirzepatide's effects on metabolic health and weight are dependent on continued use.
3. Weight Reduction in Adults With Type 2 Diabetes
The SURMOUNT-2 trial published in the Lancet in 2023 by Garvey and colleagues enrolled 938 adults with both obesity and T2D over 72 weeks, testing only the 10 mg and 15 mg doses (the 5 mg dose was not evaluated in this trial). Mean weight reductions were 12.8% (10 mg) and 14.7% (15 mg) compared to 3.2% for placebo, with treatment differences of 9.6 percentage points (95% CI 8.1–11.1) and 11.6 percentage points (95% CI 10.1–13.0), respectively (both P < 0.0001). Baseline mean HbA1c was 8.02%, and 79–83% of tirzepatide participants achieved at least 5% weight reduction versus 32% with placebo. This trial established that tirzepatide's weight-reducing effects persist in individuals with T2D, though the magnitude was somewhat lower than in SURMOUNT-1, consistent with the known attenuating effect of diabetes on weight loss outcomes. These results support the use of tirzepatide in individuals managing both conditions concurrently.
4. Obstructive Sleep Apnea
The SURMOUNT-OSA trial published in the New England Journal of Medicine in 2024 by Malhotra and colleagues enrolled 469 participants over 52 weeks and evaluated tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity. At the maximum tolerated dose of 10 or 15 mg, tirzepatide reduced the apnea-hypopnea index (AHI) by 25.3 events per hour (95% CI 21.2–29.3) in participants not using positive airway pressure therapy — a treatment difference of 20.0 events per hour versus placebo (95% CI 14.2–25.8; P < 0.001) — and by 29.3 events per hour (95% CI 25.4–33.2) in PAP users, a treatment difference of 23.8 events per hour versus placebo (95% CI 17.9–29.6; P < 0.001). Secondary outcomes included improvements in oxygen saturation, sleep quality scores, and waist circumference. This trial supported the 2024 FDA approval of Zepbound for OSA. The mechanism is primarily mediated through weight reduction and improvements in upper airway anatomy. Sleep quality biomarkers are among the relevant downstream measures for this indication.
5. Cardiovascular Outcomes
Tirzepatide's cardiovascular profile has been evaluated across multiple trials. A pre-specified meta-analysis of the SURPASS program published by Sattar and colleagues in Nature Medicine in 2022, pooling 7,215 participants (4,887 tirzepatide and 2,328 controls) across seven trials spanning 26 to 108 weeks, reported a hazard ratio for MACE-4 (composite of cardiovascular death, non-fatal MI, non-fatal stroke, and hospitalization for unstable angina) of 0.80 (95% CI 0.57–1.11) versus comparators including insulin glargine, insulin degludec, and placebo in adults with T2D. A separate phase 3 trial published by Packer and colleagues in the New England Journal of Medicine in 2024, the SUMMIT trial enrolling 731 patients (364 tirzepatide, 367 placebo) with a median follow-up of 104 weeks, reported a hazard ratio of 0.62 (95% CI 0.41–0.95; P = 0.026) for the composite of cardiovascular death or worsening heart failure — a 38% relative risk reduction — in patients with HFpEF and BMI of 30 or greater versus placebo. A 2025 Nature Medicine editorial — a commentary, not original research — discussed emerging real-world evidence suggesting comparable cardiovascular benefits for tirzepatide and semaglutide in T2D patients, though dedicated randomized cardiovascular outcome trial data for tirzepatide are still pending. Dedicated cardiovascular outcome trial data are anticipated from the ongoing SURMOUNT-MMO study. Cardiovascular health biomarkers including lipid panels and blood pressure are relevant monitoring markers.
6. Lipid and Cardiometabolic Markers
Beyond glycemic effects, tirzepatide produces meaningful changes in lipid parameters. A 2022 systematic review in the International Journal of Molecular Sciences by Forzano and colleagues, reviewing data from the SURPASS 1–5 phase 3 trials and SURMOUNT-1 enrolling more than 7,000 participants with T2D, documented dose-dependent reductions in LDL cholesterol and triglycerides across all tirzepatide arms compared to placebo and active comparators including insulin glargine and semaglutide 1.0 mg, alongside improvements in systolic blood pressure and markers of systemic inflammation. These effects appear to be partially independent of weight loss, reflecting tirzepatide's direct activity on GIP receptors in adipose tissue and hepatic lipid metabolism. Monitoring triglycerides and LDL at baseline and during therapy provides objective evidence of these secondary cardiometabolic effects.
7. Prediabetes and T2D Prevention
A 176-week extension of SURMOUNT-1 (NCT04184622) published by Jastreboff and colleagues in the New England Journal of Medicine in 2025 evaluated 1,032 participants with obesity and prediabetes randomized to tirzepatide 5 mg, 10 mg, or 15 mg or placebo. At 176 weeks, mean weight reductions were 12.3% (5 mg), 18.7% (10 mg), and 19.7% (15 mg) versus 1.3% with placebo. Type 2 diabetes developed in only 1.3% of tirzepatide-treated participants compared to 13.3% receiving placebo, a hazard ratio of 0.07 (95% CI 0.0–0.1; P < 0.001). This finding extends tirzepatide's clinical relevance beyond those with established T2D to individuals with elevated metabolic risk who have not yet crossed the diagnostic threshold. Baseline fasting insulin and HbA1c assessments are central to evaluating this risk profile.
Tirzepatide vs. Semaglutide: Key Differences
Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates GLP-1 receptors only. In head-to-head and comparative evidence, tirzepatide consistently produces greater weight reduction and HbA1c lowering than semaglutide, though both compounds carry similar gastrointestinal adverse event profiles.
The most rigorous comparative evidence comes from network meta-analyses and real-world studies rather than a single randomized controlled trial. A 2025 meta-analysis in Cureus by Munawar and colleagues, pooling seven direct comparative studies with 28,980 participants, found tirzepatide associated with significantly higher odds of achieving 10% or greater weight loss compared to semaglutide (OR 0.21; 95% CI 0.06–0.78 favoring tirzepatide) and a standardized mean difference in weight loss of 0.75 (95% CI 0.52–0.92). The Karagiannis 2024 Diabetologia meta-analysis confirmed more pronounced HbA1c and weight reduction for tirzepatide versus semaglutide in T2D across network meta-analysis. A real-world cohort study published by Rodriguez and colleagues in JAMA Internal Medicine in 2024, using propensity-score matching across 18,386 adults with overweight or obesity observed from May 2022 through November 2023, found tirzepatide associated with 2.4 percentage points greater weight loss than semaglutide at 3 months, 4.3 points at 6 months, and 6.9 points at 12 months, with a hazard ratio for achieving at least 10% weight loss of 2.54 (95% CI 2.37–2.73) favoring tirzepatide, and similar GI adverse event rates.
These comparisons involve specific doses (semaglutide 1.0 mg or 2.4 mg vs. tirzepatide 5-15 mg), specific populations, and specific study designs. Cross-trial comparisons should be interpreted with attention to those differences. Semaglutide has more extensive cardiovascular outcome trial data, including the SELECT trial by Lincoff and colleagues, which randomized 17,604 adults aged 45 or older with pre-existing cardiovascular disease and BMI of 27 or greater (without diabetes) to semaglutide 2.4 mg weekly or placebo over a mean 39.8 months and reported a hazard ratio for MACE of 0.80 (95% CI 0.72–0.90; P < 0.001). Tirzepatide's dedicated cardiovascular outcome trial is ongoing. Mechanism, evidence base, formulation availability, and individual clinical factors all inform the prescribing decision, which requires evaluation by a licensed provider.
Tirzepatide Formulations
Tirzepatide is available as a once-weekly subcutaneous injection. Brand-name formulations (Mounjaro for T2D, Zepbound for obesity and OSA) are manufactured by Eli Lilly and are available through specialty and retail pharmacies with a valid prescription. Compounded tirzepatide has been available from 503A compounding pharmacies during periods of FDA-declared shortage. The FDA removed tirzepatide from the shortage list in December 2024 via Declaratory Order, and enforcement discretion for 503A compounding ended in February 2025. As of April 2026, providers should confirm current compounding status and regulatory requirements. Compounded medications are prepared by a licensed compounding pharmacy and are not FDA-approved. They have not been evaluated by the FDA for safety, efficacy, or quality in the same manner as commercially manufactured branded products. Compounded tirzepatide may differ from the branded version in formulation, concentration, and inactive ingredients. The FDA has issued safety communications noting that compounded products may not meet the same quality standards as approved formulations. Dose titration protocols are provider-determined based on tolerability and clinical response.
Biomarkers to Monitor With Tirzepatide
A licensed provider will determine the appropriate monitoring schedule. The following biomarkers are clinically relevant given tirzepatide's mechanism and therapeutic effects:
- HbA1c: The primary glycemic monitoring marker for tirzepatide therapy. Measures average blood glucose over approximately 90 days. Meaningful reductions are typically observed at 12 to 24 weeks of therapy. Baseline and follow-up HbA1c values quantify glycemic response. Reference ranges vary by lab; providers interpret in context of individual clinical goals.
- Fasting glucose: Provides a shorter-horizon glycemic reference point than HbA1c. Relevant at baseline to characterize glycemic status and at follow-up to track incremental changes. Fasting glucose is particularly informative in the prediabetes range (100-125 mg/dL) where tirzepatide may delay progression.
- Fasting insulin: Tirzepatide improves insulin sensitivity through GIP and GLP-1 receptor co-activation. Baseline fasting insulin establishes whether insulin resistance is present and provides context for interpreting subsequent HbA1c changes.
- Lipid panel (LDL-C, triglycerides, HDL-C, non-HDL-C): SURPASS trial data demonstrated dose-dependent improvements in LDL cholesterol, triglycerides, and HDL cholesterol. Baseline lipid assessment and follow-up monitoring at 3 to 6 months capture these cardiometabolic effects. Triglycerides are among the most responsive markers. Reference ranges vary by lab and cardiovascular risk profile.
- Complete metabolic panel (CMP): Covers liver function (AST, ALT, alkaline phosphatase) and kidney function (creatinine, BUN, eGFR). Liver enzyme elevations have been reported with GLP-1 receptor agonists in some populations; baseline and periodic monitoring are standard clinical practice. eGFR is particularly relevant in individuals with pre-existing renal conditions, as tirzepatide can reduce renal perfusion pressure through blood pressure and weight effects.
- Complete blood count (CBC): Relevant at baseline to rule out underlying conditions that may affect tolerability, including anemia, which can confound fatigue-related side effect assessment.
- hs-CRP: A sensitive marker of systemic inflammation. The SURPASS trials reported reductions in inflammatory markers with tirzepatide. Monitoring hs-CRP alongside weight and glycemic markers provides an additional cardiometabolic reference point.
- Blood pressure: SURPASS data document consistent reductions in systolic and diastolic blood pressure with tirzepatide across all doses. Tracking blood pressure before and during therapy quantifies this effect, particularly in individuals with pre-existing hypertension.
HbA1c, fasting glucose, fasting insulin, and a lipid panel are the core markers for evaluating cardiometabolic baseline before starting tirzepatide. A complete metabolic panel confirms organ function. For individuals with existing cardiovascular risk factors, a comprehensive cardiovascular biomarker assessment provides additional clinical context that informs prescribing decisions.
What Tirzepatide Is Typically Prescribed For
Providers typically evaluate candidates for tirzepatide based on FDA-approved indications: type 2 diabetes requiring glycemic management, chronic weight management in adults with BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or cardiovascular disease), and moderate-to-severe obstructive sleep apnea with obesity. Baseline bloodwork confirming glycemic status, lipid profile, and organ function is standard practice before initiation. Tirzepatide requires a prescription from a licensed provider. Superpower Health facilitates access through its licensed provider network and compounding pharmacy partners.
Who Should Not Use Tirzepatide
A licensed provider will evaluate individual risk factors before prescribing. The following are contraindications or conditions requiring additional clinical scrutiny based on the FDA prescribing information:
- Personal or family history of medullary thyroid carcinoma (MTC), as GLP-1 receptor agonists have been associated with thyroid C-cell tumors in rodent studies; human relevance is uncertain but the prescribing information carries a boxed warning
- Multiple endocrine neoplasia syndrome type 2 (MEN 2), which includes an elevated risk of MTC
- Known hypersensitivity to tirzepatide or any component of the formulation
- Pregnancy, as GLP-1 receptor agonists may cause fetal harm; adequate contraception is recommended during use and for a period following discontinuation per provider guidance
- Severe gastrointestinal disease, including gastroparesis, as tirzepatide slows gastric emptying and may worsen these conditions
- History of pancreatitis, as GLP-1 receptor agonists have been associated with acute pancreatitis; the causal relationship remains under evaluation
- Diabetic retinopathy requiring treatment, as rapid improvements in glycemic control with intensive therapy have been associated with early worsening of retinopathy
Side Effects and Safety Considerations
The most common side effects of tirzepatide are gastrointestinal and are generally dose-dependent. They are most prominent during dose escalation and tend to diminish over time in most patients. A 2023 meta-analysis in the Journal of the Endocrine Society by Mishra and colleagues, pooling 10 clinical trials with 6,836 participants, reported dose-dependent GI adverse event rates of 39% (95% CI 35–43%) at 5 mg, 46% (95% CI 42–49%) at 10 mg, and 49% (95% CI 38–60%) at 15 mg, with drug discontinuation due to adverse events reaching 10% at the 15 mg dose; severe hypoglycemia and fatal adverse events each occurred in 1% or fewer of participants across all doses.
Common (reported in clinical studies):
- Nausea (most common, particularly during dose escalation; reported in approximately 24-33% of participants in SURMOUNT-1 depending on dose)
- Diarrhea (reported in approximately 17-21% in SURMOUNT-1)
- Vomiting (reported in approximately 8-13% in SURMOUNT-1)
- Constipation (reported in 7-11% in SURMOUNT-1)
- Injection-site reactions, including erythema, pruritus, and swelling (generally mild and transient)
- Decreased appetite (a primary mechanism of action; expected and reported across trials)
Less common but reported:
- Acute pancreatitis: discontinue and contact your provider promptly if you experience severe, persistent abdominal pain
- Hypoglycemia: primarily in individuals using concurrent insulin or sulfonylureas; risk is low with tirzepatide monotherapy
- Cholelithiasis (gallstones): observed with weight loss in general; reported in GLP-1 RA class; alert provider to right upper quadrant pain
- Tachycardia: a modest increase in resting heart rate (2-4 bpm) has been observed across GLP-1 RA class trials; clinical significance is uncertain in most patients
- Psychiatric symptoms (depression, anxiety): reported in 1.2% of pharmacovigilance reports for the GLP-1 RA class per a 2024 pharmacovigilance study in the International Journal of Clinical Pharmacy by Tobaiqy and colleagues; alert provider to changes in mood or behavior
- Hair loss (telogen effluvium): commonly observed in the context of rapid weight loss rather than as a direct drug effect; typically self-resolving
Is Tirzepatide Legal?
As of April 2026, tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) and for chronic weight management and obstructive sleep apnea in adults with obesity (Zepbound). Tirzepatide is not FDA-approved for any other indications. The safety and efficacy of tirzepatide for any use other than the approved indications have not been established through adequate and well-controlled clinical trials reviewed by the FDA.
Tirzepatide has been compounded under Section 503A during periods of FDA-declared shortage. FDA shortage status and associated compounding permissions are subject to change; as of April 2026, the FDA removed tirzepatide from the shortage list for all strengths in a December 2024 Declaratory Order, and enforcement discretion for 503A compounding ended in February 2025. Providers and patients should confirm current compounding status. Compounded tirzepatide is not equivalent to FDA-approved Mounjaro or Zepbound and has not undergone FDA review. It is not available over the counter.
Tirzepatide is not on the 2026 WADA Prohibited List for competition use, and no specific athletic ban applies. Its primary indications are metabolic and related to chronic disease management rather than athletic performance enhancement.
Understanding Your Baseline Before Starting Tirzepatide
Tirzepatide produces its most meaningful effects in individuals whose baseline metabolic profile documents the clinical need: elevated HbA1c, impaired fasting glucose, insulin resistance, dyslipidemia, or body composition markers consistent with obesity and cardiometabolic risk. Testing before initiation creates the reference point against which response at 12, 24, and 52 weeks can be measured. HbA1c and fasting glucose establish the glycemic baseline. Fasting insulin characterizes insulin resistance. A complete lipid panel captures the cardiometabolic context. A metabolic panel rules out contraindications. Without these baselines, the clinical significance of changes during therapy is difficult to evaluate objectively.
That principle — test first, then decide — is central to Superpower's approach to preventive health: the belief that every clinical decision should be grounded in what your bloodwork actually shows, not assumptions about what might be happening.
Frequently Asked Questions
What is the difference between tirzepatide and semaglutide?
Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates only GLP-1 receptors. In comparative trials and network meta-analyses, tirzepatide has produced greater mean weight reduction and HbA1c lowering than semaglutide at the doses studied. Semaglutide has more extensive dedicated cardiovascular outcome trial data, including the SELECT trial, which randomized 17,604 non-diabetic adults with pre-existing cardiovascular disease and BMI of 27 or greater to semaglutide 2.4 mg weekly or placebo over a mean 39.8 months and reported a hazard ratio of 0.80 (95% CI 0.72–0.90) for MACE. Both carry similar gastrointestinal side effect profiles. The prescribing decision requires clinical evaluation.
What happens to your body when you stop tirzepatide?
Weight regain is well-documented after discontinuation. In SURMOUNT-4, participants who switched from tirzepatide to placebo regained approximately 14% of body weight within 52 weeks, erasing much of the initial loss. Glycemic markers also trend toward pre-treatment values over time. This reflects the ongoing nature of the hormonal pathways tirzepatide supports; the effects are not permanent and are dependent on continued use. Providers typically discuss maintenance strategies before initiating therapy.
Is tirzepatide FDA-approved?
Yes. Tirzepatide is FDA-approved under the brand name Mounjaro for the management of type 2 diabetes in adults, approved in May 2022. Under the brand name Zepbound, it received FDA approval in November 2023 for chronic weight management in adults with obesity or overweight with weight-related comorbidities, and in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. No other uses have been approved by the FDA.
How much weight can you lose on tirzepatide in 3 months?
In SURMOUNT-1, participants taking tirzepatide achieved mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo at the 72-week primary endpoint. The trial included a 20-week dose-escalation period; published interim timepoint data at 12 weeks are approximate and derived from graphical figures rather than pre-specified analyses, with estimated reductions of roughly 5–7% depending on dose and individual characteristics. Results varied substantially across participants. Weight loss is most consistent in individuals who also implement dietary and lifestyle changes concurrent with medication use, as studied in the clinical trials.
Can you take tirzepatide without being diabetic?
Yes. Tirzepatide (as Zepbound) is FDA-approved for chronic weight management in adults without type 2 diabetes who have a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. The SURMOUNT-1 trial specifically enrolled participants without type 2 diabetes and documented the 20.9% mean weight reduction at the 15 mg dose at 72 weeks.
Is compounded tirzepatide the same as brand-name?
No. Compounded tirzepatide is not FDA-approved and has not been reviewed by the FDA for safety, efficacy, or manufacturing quality. It is prepared by 503A compounding pharmacies under state pharmacy board oversight. The FDA has issued safety communications noting that compounded products may differ from FDA-approved formulations in quality, potency, and sterility. Availability for compounding is also tied to FDA shortage status, which changes over time. A licensed provider can clarify current options.
Does tirzepatide cause hair loss?
Hair thinning associated with tirzepatide is typically attributed to telogen effluvium, a form of diffuse hair shedding triggered by significant physiological stress, including rapid weight loss. It is not considered a direct pharmacological effect of the drug. In clinical trials, hair loss was reported at low rates. Telogen effluvium is generally self-limiting and resolves within 3 to 6 months as the body adjusts to a new stable weight. Nutritional adequacy during weight loss, particularly protein intake, is clinically relevant to hair follicle maintenance.
IMPORTANT SAFETY INFORMATION
Tirzepatide is an FDA-approved prescription medication marketed as Mounjaro (type 2 diabetes), Zepbound (chronic weight management), and approved for moderate-to-severe obstructive sleep apnea in adults with obesity. The compounded formulation available through Superpower is NOT the FDA-approved drug product. Compounded tirzepatide has not been reviewed by the FDA for safety, efficacy, or manufacturing quality. Clinical trial results cited on this page were generated using FDA-approved branded formulations and may not apply to compounded versions. The availability of compounded tirzepatide is subject to ongoing regulatory developments regarding drug shortage status and FDA enforcement policy. Superpower is a technology platform; Superpower does not prescribe or dispense medications.
Boxed warning (from FDA-approved labeling): Tirzepatide causes thyroid C-cell tumors in rodents. It is unknown whether it causes MTC in humans. Do not use if you or any family member has had MTC or MEN 2.
Warnings: pancreatitis, gallbladder events, hypoglycemia, kidney injury, serious allergic reactions, gastroparesis, diabetic retinopathy complications.
Common side effects: nausea, diarrhea, vomiting, constipation, decreased appetite, abdominal pain, injection site reactions.
Pregnancy: not recommended. Discontinue at least 2 months before a planned pregnancy.
Not a complete list of risks. Full FDA-approved prescribing information at dailymed.nlm.nih.gov.
.avif)
.avif)
.avif)
.avif)
.avif)
.jpg)
.avif)
